solute carrier family 9 member C2 (putative)Genealiases: NHE11 · SLC9A11
Q-omics provides the consensus-scored SLC9C2 profile across patient tissues and cancer cell-line models. SLC9C2 expression is associated with patient survival in 19 of 34 cancer types, with the highest sampling consensus in KIRC. Among the 18 cancer types available for tumor–normal comparison, SLC9C2 is differentially expressed in 9, with the highest sampling consensus in LUSC. Additionally, SLC9C2 RNA expression shows 14,435 significant gene co-expression associations, with the highest sampling consensus in KIRP. Together, these results highlight KIRC, LUSC, and KIRP as cancer lineages where SLC9C2 shows reproducible signals across survival, tumor–normal expression, and patient cross-omics analyses.
Every result is evaluated using two consensus scores. Sampling consensus measures how consistently a finding is reproduced within a cancer lineage across different conditions. Lineage consensus measures how broadly the result is shared across cancer types, distinguishing pan-cancer signals from lineage-specific patterns.
Premium analyses for SLC9C2 — synthetic lethality, tumor antigen, and pembrolizumab response.
This table summarizes SLC9C2 survival associations across molecular data types. SLC9C2 RNA expression shows survival associations in the most cancer types (19), followed by mutation status (7). The rightmost column indicates the cancer type with the highest sampling consensus for each molecular layer.
This table ranks reproducible SLC9C2 RNA expression–survival associations across cancer types. High SLC9C2 expression shows unfavorable associations in KIRC, LGG and LAML, but favorable associations in MESO, HNSC and SKCM. The KIRC Kaplan–Meier curve shows clear separation, with the high-expression group declining faster, consistent with the unfavorable association (log-rank p < 0.001). Together, the overview and detailed table identify KIRC as the clearest survival context for SLC9C2 RNA expression.
This table summarizes SLC9C2 tumor–normal expression differences by data type. RNA shows broader differences across cancer types, with a lineage consensus of 9. The strongest signals are observed in LUSC for RNA.
This table ranks reproducible tumor–normal expression differences for SLC9C2. A negative fold-change indicates higher expression in normal tissue than in tumor tissue. SLC9C2 shows lower tumor expression in LUSC, KICH, UCEC, LUAD and THCA and higher tumor expression in HNSC. The LUSC box plot shows higher SLC9C2 RNA expression in normal versus tumor tissue (log2 FC = −0.273, t-test p < 0.001).
This table shows molecular features associated with SLC9C2 in patient tissues and cancer cell lines. In patient samples, SLC9C2 shows the broadest associations at the RNA and protein expression levels, with KIRP recurring as the lineage with the largest associated feature set. In cancer cell lines, SLC9C2 RNA and mutation anchors are most strongly linked to RNA-expression features, especially in SOFT_TISSUE, while CRISPR and shRNA rows add functional-dependency signals in STOMACH and LARGE_INTESTINE.
